CRISPR Therapeutics (NASDAQ:CRSP) CEO Samarth Kulkarni Sells 30,000 Shares of Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 30,000 shares of the company’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $51.75, for a total transaction of $1,552,500.00. Following the sale, the chief executive officer owned 194,201 shares of the company’s stock, valued at $10,049,901.75. The trade was a 13.38% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Samarth Kulkarni also recently made the following trade(s):

• On Thursday, January 22nd, Samarth Kulkarni sold 60,000 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $60.23, for a total value of $3,613,800.00.

CRISPR Therapeutics Stock Up 10.8%

Shares of CRISPR Therapeutics stock opened at $60.66 on Friday. CRISPR Therapeutics AG has a 12 month low of $30.04 and a 12 month high of $78.48. The business has a fifty day simple moving average of $54.88 and a 200 day simple moving average of $58.35. The stock has a market cap of $5.78 billion, a PE ratio of -10.85 and a beta of 1.70.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Monday, November 10th. The company reported ($1.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.15. The firm had revenue of $0.89 million for the quarter, compared to analysts’ expectations of $8.74 million. CRISPR Therapeutics had a negative return on equity of 21.23% and a negative net margin of 1,273.70%. Analysts expect that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Institutional Investors Weigh In On CRISPR Therapeutics

Several institutional investors have recently bought and sold shares of CRSP. Optiver Holding B.V. boosted its position in CRISPR Therapeutics by 71.4% during the 3rd quarter. Optiver Holding B.V. now owns 504 shares of the company’s stock worth $33,000 after acquiring an additional 210 shares during the last quarter. Thompson Investment Management Inc. acquired a new position in CRISPR Therapeutics during the third quarter worth $33,000. Strategic Advocates LLC bought a new position in CRISPR Therapeutics in the third quarter valued at $34,000. Thurston Springer Miller Herd & Titak Inc. grew its position in CRISPR Therapeutics by 196.9% in the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 576 shares of the company’s stock valued at $30,000 after purchasing an additional 382 shares in the last quarter. Finally, Bogart Wealth LLC lifted its position in CRISPR Therapeutics by 333.3% during the 3rd quarter. Bogart Wealth LLC now owns 650 shares of the company’s stock worth $42,000 after buying an additional 500 shares in the last quarter. Institutional investors own 69.20% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on CRSP. Wedbush cut their target price on shares of CRISPR Therapeutics from $13.00 to $9.00 and set an “outperform” rating on the stock in a report on Wednesday, November 5th. Bank of America lifted their target price on CRISPR Therapeutics from $78.00 to $93.00 and gave the stock a “buy” rating in a report on Friday, October 17th. Needham & Company LLC reissued a “buy” rating and issued a $80.00 target price on shares of CRISPR Therapeutics in a research note on Tuesday, December 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CRISPR Therapeutics in a research report on Wednesday. Finally, Citizens Jmp reiterated a “market outperform” rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a research report on Tuesday, December 23rd. Twelve research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $68.35.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.